Prologue Journal

J&J will acquire cancer-treatment developer Ambrx in a $2 billion cash deal, the companies said.

• prologu5
• 01/09/202401/09/2024

Wall Street Journal

J&J will acquire cancer-treatment developer Ambrx in a $2 billion cash deal, the companies said.

https://www.wsj.com/health/pharma/johnson-johnson-to-acquire-cancer-treatment-developer-amrbx-for-2b-f7fbafea